MX379043B - Uso de sobetirome en el tratamiento de enfermedades de mielinización. - Google Patents
Uso de sobetirome en el tratamiento de enfermedades de mielinización.Info
- Publication number
- MX379043B MX379043B MX2015015228A MX2015015228A MX379043B MX 379043 B MX379043 B MX 379043B MX 2015015228 A MX2015015228 A MX 2015015228A MX 2015015228 A MX2015015228 A MX 2015015228A MX 379043 B MX379043 B MX 379043B
- Authority
- MX
- Mexico
- Prior art keywords
- sobetirome
- myelinization
- diseases
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PCT/US2014/014943 WO2014178931A1 (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015228A MX2015015228A (es) | 2016-10-03 |
| MX379043B true MX379043B (es) | 2025-03-10 |
Family
ID=51843844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015228A MX379043B (es) | 2013-05-03 | 2014-02-05 | Uso de sobetirome en el tratamiento de enfermedades de mielinización. |
| MX2021000538A MX2021000538A (es) | 2013-05-03 | 2015-10-30 | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000538A MX2021000538A (es) | 2013-05-03 | 2015-10-30 | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10226438B2 (enExample) |
| EP (1) | EP2991670B8 (enExample) |
| JP (4) | JP2016517883A (enExample) |
| CN (1) | CN105431163A (enExample) |
| AU (1) | AU2014260468A1 (enExample) |
| BR (1) | BR112015027682A2 (enExample) |
| CA (1) | CA2911309A1 (enExample) |
| ES (1) | ES2745532T3 (enExample) |
| MX (2) | MX379043B (enExample) |
| RU (1) | RU2015151216A (enExample) |
| SG (2) | SG10201709090UA (enExample) |
| WO (2) | WO2014178892A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| CA2946422C (en) | 2014-04-30 | 2019-03-05 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| JP6342575B2 (ja) | 2014-08-13 | 2018-06-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳腫瘍への選択的デンドリマー送達 |
| CA3003589C (en) * | 2015-10-29 | 2021-12-07 | The Johns Hopkins University | Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
| BR112018071559B1 (pt) * | 2016-04-22 | 2024-02-06 | Viking Therapeutics, Inc | Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x |
| AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
| DK3457851T3 (da) | 2016-05-18 | 2021-09-20 | Univ Oregon Health & Science | Derivater af sobetirom |
| US11325886B2 (en) | 2016-08-12 | 2022-05-10 | Oregon Health & Science University | Amide compounds, pharmaceutical compositions thereof, and methods of using the same |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| IL270169B2 (en) | 2017-04-27 | 2024-08-01 | Univ Johns Hopkins | Dendrimer preparations for use in angiography |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| EP3644983B1 (en) | 2017-06-29 | 2023-10-25 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| AU2018302641B2 (en) | 2017-07-18 | 2024-12-19 | Keio University | Anti-bacterial composition against Th1 cell-inducing bacteria |
| US11918657B2 (en) | 2017-11-10 | 2024-03-05 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| AU2019397067A1 (en) | 2018-12-12 | 2021-07-22 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| WO2020180624A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| US12466781B2 (en) | 2019-11-29 | 2025-11-11 | Autobahn Therapeutics, Inc. | Thyromimetics |
| JP7759322B2 (ja) | 2019-12-04 | 2025-10-23 | アシュバッタ セラピューティクス， インコーポレイテッド | 眼に薬物送達するためのデンドリマー組成物および方法 |
| CN111116684B (zh) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物 |
| WO2021257851A1 (en) | 2020-06-17 | 2021-12-23 | Autobahn Therapeutics, Inc. | Thyromimetics |
| US12590072B2 (en) | 2020-06-17 | 2026-03-31 | Autobahn Therapeutics, Inc. | Thyromimetics |
| WO2023081458A1 (en) * | 2021-11-08 | 2023-05-11 | Rutgers, The State University Of New Jersey | Systems and methods for diagnosis and/or treating demyelinating neuropathy |
| CN115569233B (zh) * | 2022-10-17 | 2023-07-14 | 湖南大学 | 既能吸光又能与自由基反应的高效光抑制剂的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US6236946B1 (en) | 1995-12-13 | 2001-05-22 | Thomas S. Scanlan | Nuclear receptor ligands and ligand binding domains |
| WO1998007435A1 (en) | 1996-08-20 | 1998-02-26 | The Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| CA2335551C (en) | 1998-06-30 | 2009-03-03 | The Regents Of The University Of California | Thyroid hormone analogues and methods for their preparation |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| CA2539288C (en) * | 2003-09-15 | 2015-05-12 | Shaker A. Mousa | Thyroid hormone analogs and methods of use |
| WO2006012015A2 (en) * | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| CN101102758B (zh) * | 2004-09-15 | 2011-11-16 | 奥德威研究院 | 促进血管新生的甲状腺激素类似物 |
| WO2006105205A1 (en) | 2005-03-29 | 2006-10-05 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| CN101600450A (zh) | 2006-10-20 | 2009-12-09 | 比奥根艾迪克Ma公司 | 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗 |
| WO2008052354A1 (en) * | 2006-11-03 | 2008-05-08 | University Of Saskatchewan | Method of treating demyelination diseases |
| FI20075245A0 (fi) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
| US8138201B2 (en) | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2278999B1 (en) * | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| EP2437730A4 (en) | 2009-05-20 | 2014-02-26 | Lingual Consegna Pty Ltd | ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION |
| TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| PT2651357T (pt) | 2010-12-16 | 2020-06-17 | Sunovion Pharmaceuticals Inc | Películas sublinguais |
| JP6060268B2 (ja) * | 2012-10-25 | 2017-01-11 | ボルボ トラック コーポレイション | 車両用電子制御エアブレーキシステム、そのようなシステムを備える車両及びそのようなシステムを制御する方法 |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
-
2013
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en not_active Ceased
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/ja not_active Withdrawn
-
2014
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/ja active Active
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/pt not_active IP Right Cessation
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/zh active Pending
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en not_active Ceased
- 2014-02-05 ES ES14791718T patent/ES2745532T3/es active Active
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/ru not_active Application Discontinuation
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 MX MX2015015228A patent/MX379043B/es unknown
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/es unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/ja active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/ja active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6360552B6 (ja) | 2018-08-15 |
| US10226438B2 (en) | 2019-03-12 |
| SG10201709090UA (en) | 2017-12-28 |
| CN105431163A (zh) | 2016-03-23 |
| AU2014260468A1 (en) | 2015-11-19 |
| JP6360552B2 (ja) | 2018-07-18 |
| HK1222552A1 (en) | 2017-07-07 |
| JP2018141024A (ja) | 2018-09-13 |
| RU2015151216A (ru) | 2017-06-08 |
| JP2018162321A (ja) | 2018-10-18 |
| US20190175531A1 (en) | 2019-06-13 |
| WO2014178892A1 (en) | 2014-11-06 |
| EP2991670A4 (en) | 2017-01-18 |
| US20200405669A1 (en) | 2020-12-31 |
| JP2016517884A (ja) | 2016-06-20 |
| EP2991670B1 (en) | 2019-07-03 |
| EP2991670A1 (en) | 2016-03-09 |
| BR112015027682A2 (pt) | 2017-08-29 |
| CA2911309A1 (en) | 2014-11-06 |
| US11510887B2 (en) | 2022-11-29 |
| SG11201509012QA (en) | 2015-11-27 |
| WO2014178931A1 (en) | 2014-11-06 |
| MX2015015228A (es) | 2016-10-03 |
| JP2016517883A (ja) | 2016-06-20 |
| WO2014178892A8 (en) | 2015-12-17 |
| EP2991670B8 (en) | 2019-09-11 |
| US20160081955A1 (en) | 2016-03-24 |
| WO2014178931A8 (en) | 2015-11-26 |
| ES2745532T3 (es) | 2020-03-02 |
| MX2021000538A (es) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379043B (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinización. | |
| MX2024004439A (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| IL283771A (en) | Anellosomes for delivering intracellular therapeutic modalities | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| HUE045148T2 (hu) | Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére | |
| TR201908151T4 (tr) | İzoindolin türevleri. | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| CY1122418T1 (el) | Αγωγη ερυθρομελαλγιας | |
| IL258610B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| MX2017014540A (es) | Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus. | |
| EA201692013A1 (ru) | Новое применение n,n-бис-2-меркаптоэтил-изофталамида | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| BR112016028081A2 (pt) | Novos compostos como agentes antituberculares | |
| CY1122769T1 (el) | Αγωγη της περιφερικης νευροπαθειας των μικρων ινων | |
| PL3352777T3 (pl) | Engrailed do stosowania w leczeniu uszkodzenia dna u pacjentów cierpiących na chorobę parkinsona |